Product safety spillovers and market viability for biologic drugs
John Romley and
Tiffany Shih ()
Additional contact information
Tiffany Shih: Precision Health Economics
International Journal of Health Economics and Management, 2017, vol. 17, issue 2, 135-158
Abstract When a pharmaceutical manufacturer experiences a safety problem, negative impacts on profitability can spread to its competitors. Reduced consumer confidence, product recalls, and litigation are limited to the responsible manufacturer only if that manufacturer can be clearly linked to the safety problem. We analyze the impact of “accountability” for safety problems on manufacturer entry decisions and investments to mitigate risk. Consistent with prior research, we find investment levels increase with accountability in a duopoly market, and that accountability can thus enhance market viability and improve consumer welfare. However, we also analyze the impact of accountability on entry of a competitor, after the originator’s exclusivity has expired. Accountability promotes the development of a robust market by raising expected profits, particularly for an entrant with a relatively low likelihood of a safety problem. Yet entry need not improve consumer welfare, and may benefit the incumbent in our model. In contrast to the traditional entry deterrence mechanism, when accountability is sufficiently low, increased incumbent investment encourages entry. Our analysis has important implications for biologic drugs, insofar as pathways for entry by “biosimilars” have been established in Europe and the United States, and informs pharmacovigilance and other accountability policies for biologics.
Keywords: Pharmaceutical quality; Pharmaceutical competition; Pharmaceutical regulation; Biologic drugs (search for similar items in EconPapers)
JEL-codes: I18 D62 L65 L13 (search for similar items in EconPapers)
References: View references in EconPapers View complete reference list from CitEc
Citations: Track citations by RSS feed
Downloads: (external link)
http://link.springer.com/10.1007/s10754-016-9208-2 Abstract (text/html)
Access to full text is restricted to subscribers.
This item may be available elsewhere in EconPapers: Search for items with the same title.
Export reference: BibTeX
RIS (EndNote, ProCite, RefMan)
Persistent link: https://EconPapers.repec.org/RePEc:kap:ijhcfe:v:17:y:2017:i:2:d:10.1007_s10754-016-9208-2
Ordering information: This journal article can be ordered from
http://www.springer. ... th/journal/10754/PS2
Access Statistics for this article
International Journal of Health Economics and Management is currently edited by Leemore Dafny, Robert Town, Mark Pauly, David Dranove and Pedro Pita Barros
More articles in International Journal of Health Economics and Management from Springer
Bibliographic data for series maintained by Sonal Shukla ().